Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from TARGET-DERM registry (RAD Winter 2023)

This is a RAD Winter 2023 presentation of the same persistent inadequate disease control study as Row 20 (Fall Clinical 2024). Earlier version of the analysis characterizing the prevalence of therapeutic inertia using clinician-reported outcomes.

TARGET-DERM AD registry used to measure the proportion of patients with moderate-to-severe AD failing to achieve AHEAD disease control targets at 3–12 months without treatment modification.

Multi-venue dissemination of therapeutic inertia prevalence findings strengthens the evidence base for prescriber education and reinforces the commercial case for high-efficacy AD therapies that reliably achieve treat-to-target thresholds.

Multi-venue therapeutic inertia prevalence evidence for AD prescriber behavior change, Treat-to-target adherence benchmarking in real-world AD for commercial and clinical strategy, Evidence base for treatment escalation guidance in moderate-to-severe AD management